• CEL-SCI Corporation (NYSE:CVM) announced Thursday that the FDA agreed to its proposal to use the PD-L1 biomarker status in selecting patients for a registrational trial for its lead cancer therapy, Multikine.
• Accordingly, the 212-subject confirmatory trial is expected to enroll newly

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。